SG Americas Securities LLC Sells 29,306 Shares of Unum Group (NYSE:UNM)

SG Americas Securities LLC reduced its stake in shares of Unum Group (NYSE:UNM) by 90.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,992 shares of the financial services provider’s stock after selling 29,306 shares during the quarter. SG Americas Securities LLC’s holdings in Unum Group were worth $135,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Silver Oak Securities Incorporated bought a new stake in shares of Unum Group during the third quarter worth $25,000. Contravisory Investment Management Inc. bought a new position in shares of Unum Group in the 4th quarter valued at about $25,000. Bangor Savings Bank grew its position in shares of Unum Group by 100.0% during the 3rd quarter. Bangor Savings Bank now owns 664 shares of the financial services provider’s stock worth $33,000 after buying an additional 332 shares during the period. Neo Ivy Capital Management bought a new stake in shares of Unum Group during the third quarter worth approximately $36,000. Finally, Arlington Trust Co LLC acquired a new position in Unum Group in the third quarter valued at approximately $38,000. 86.57% of the stock is owned by institutional investors.

Unum Group Trading Down 0.5 %

NYSE UNM opened at $50.16 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.27 and a quick ratio of 0.27. The stock’s 50-day moving average is $50.89 and its 200-day moving average is $47.56. Unum Group has a one year low of $40.04 and a one year high of $54.57. The firm has a market cap of $9.63 billion, a P/E ratio of 7.73, a P/E/G ratio of 1.00 and a beta of 0.87.

Unum Group (NYSE:UNM) last announced its earnings results on Tuesday, January 30th. The financial services provider reported $1.79 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.07). The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.14 billion. Unum Group had a return on equity of 16.03% and a net margin of 10.36%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the business posted $1.43 earnings per share. Sell-side analysts anticipate that Unum Group will post 8.18 earnings per share for the current fiscal year.

Unum Group Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 17th. Investors of record on Friday, April 26th will be paid a $0.365 dividend. This represents a $1.46 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date of this dividend is Thursday, April 25th. Unum Group’s payout ratio is presently 22.50%.

Analysts Set New Price Targets

A number of research firms have commented on UNM. StockNews.com raised shares of Unum Group from a “hold” rating to a “buy” rating in a report on Wednesday, January 31st. Morgan Stanley upped their price objective on Unum Group from $50.00 to $52.00 and gave the company an “equal weight” rating in a report on Monday. JPMorgan Chase & Co. raised their target price on Unum Group from $56.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, April 2nd. The Goldman Sachs Group boosted their target price on Unum Group from $47.00 to $52.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 31st. Finally, Wells Fargo & Company lifted their price objective on shares of Unum Group from $64.00 to $66.00 and gave the stock an “overweight” rating in a research note on Thursday, April 11th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Unum Group has a consensus rating of “Moderate Buy” and an average target price of $56.38.

Insider Buying and Selling

In other Unum Group news, CEO Richard P. Mckenney sold 50,000 shares of Unum Group stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $49.15, for a total value of $2,457,500.00. Following the sale, the chief executive officer now owns 1,076,753 shares of the company’s stock, valued at approximately $52,922,409.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Lisa G. Iglesias sold 16,000 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $50.00, for a total transaction of $800,000.00. Following the completion of the transaction, the executive vice president now owns 40,840 shares in the company, valued at $2,042,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Richard P. Mckenney sold 50,000 shares of Unum Group stock in a transaction on Friday, March 1st. The shares were sold at an average price of $49.15, for a total transaction of $2,457,500.00. Following the completion of the sale, the chief executive officer now owns 1,076,753 shares in the company, valued at $52,922,409.95. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,000 shares of company stock valued at $4,018,100. Company insiders own 0.77% of the company’s stock.

Unum Group Company Profile

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.